GETI.B

198.3

-0.23%↓

CAMX

636

-1.01%↓

VITR

135.2

+0.82%↑

ATT

68.7

-0.29%↓

ARJOB

32.68

+0.68%↑

GETI.B

198.3

-0.23%↓

CAMX

636

-1.01%↓

VITR

135.2

+0.82%↑

ATT

68.7

-0.29%↓

ARJOB

32.68

+0.68%↑

GETI.B

198.3

-0.23%↓

CAMX

636

-1.01%↓

VITR

135.2

+0.82%↑

ATT

68.7

-0.29%↓

ARJOB

32.68

+0.68%↑

GETI.B

198.3

-0.23%↓

CAMX

636

-1.01%↓

VITR

135.2

+0.82%↑

ATT

68.7

-0.29%↓

ARJOB

32.68

+0.68%↑

GETI.B

198.3

-0.23%↓

CAMX

636

-1.01%↓

VITR

135.2

+0.82%↑

ATT

68.7

-0.29%↓

ARJOB

32.68

+0.68%↑

Home・Aandelen Lijst・BioArctic AB

B
BioArctic AB

Open

220.6 2.41

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

213.8

Max

226.6

Belangrijke statistieken
By Trading Economics
Inkomsten	1.1B 1.1B
Verkoop	1.2B 1.3B
K/W Sectorgemiddelde	20.535 34.393
EPS	11.53
Winstmarge	83.379
Werknemers	116
EBITDA	1.1B 1.1B

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.7B 19B
Vorige openingsprijs	218.19
Vorige sluitingsprijs	220.6

BioArctic AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 aug 2025, 17:49 UTC

Belangrijke Marktbewegers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug 2025, 17:18 UTC

Belangrijke Marktbewegers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug 2025, 16:25 UTC

Winsten

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Global Energy Roundup: Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug 2025, 23:32 UTC

Marktinformatie

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug 2025, 23:02 UTC

Marktinformatie

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 aug 2025, 20:37 UTC

Winsten

Acquisities, Fusies, Overnames

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug 2025, 20:37 UTC

Winsten

Acquisities, Fusies, Overnames

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug 2025, 20:37 UTC

Winsten

Acquisities, Fusies, Overnames

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug 2025, 20:14 UTC

Marktinformatie

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug 2025, 19:12 UTC

Marktinformatie

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug 2025, 18:56 UTC

Marktinformatie

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug 2025, 18:31 UTC

Marktinformatie

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug 2025, 17:43 UTC

Marktinformatie

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug 2025, 17:28 UTC

Marktinformatie

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug 2025, 17:16 UTC

Marktinformatie

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug 2025, 16:42 UTC

Acquisities, Fusies, Overnames

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug 2025, 16:27 UTC

Acquisities, Fusies, Overnames

BBVA Says Sabadell Offer Remains in Effect

11 aug 2025, 16:26 UTC

Acquisities, Fusies, Overnames

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Announced TSB Sale on July 1

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Vergelijking

Prijswijziging

BioArctic AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.